Champions Oncology
CSBR
23 hedge funds and large institutions have $29.9M invested in Champions Oncology in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 2 closing their positions.
162% more capital inflows, than outflows
Capital inflows: $1.1M | Capital outflows: $422K
1.03% more ownership
Funds ownership: 41.45% → 42.49% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
8% less funds holding
Funds holding: 25 → 23 (-2)
73% less call options, than puts
Call options by funds: $17K | Put options by funds: $63K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 2 |
Morgan Stanley
New York
|
+$11.7K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$6.86K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.74K |
| 5 |
BlackRock
New York
|
+$1.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Essex Investment Management
Boston,
Massachusetts
|
-$378K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$10.8K |
| 4 |
Renaissance Technologies
New York
|
-$10.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.55K |
CSBR Hedge Fund Activity: Q2 2024 in Review
23 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q2 2024, worth a combined $29.9M — up 8.2% from $27.6M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CSBR and 0 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $1.08M. The largest seller was Essex Investment Management, exiting entirely with an estimated $378K sold.
- 23 institutional investors held Champions Oncology (CSBR) as of Q2 2024, down from 25 in Q1 2024.
- Funds reported $29.9M of Champions Oncology stock for Q2 2024, up 8.2% quarter-over-quarter.
- 0 funds opened new Champions Oncology positions in Q2 2024 and 2 closed out, a net change of -2 holders.
- The largest Champions Oncology buyer in Q2 2024 was Vanguard Group, an estimated $1.08M added.
- The largest Champions Oncology seller in Q2 2024 was Essex Investment Management, an estimated $378K sold.
Based on aggregated 13F filings for Q2 2024.